Assessing treatment effects on axonal loss - Evidence from MRI monitored clinical trials

Journal of Neurology, Supplement

Volumn 251, Issue 4, 2004, Pages

  Barkhof, Frederik ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Axonal loss; Cerebral atrophy; Magnetic resonance imaging (MRI); Magnetisation transfer ratio (MTR); Multiple sclerosis (MS); Relapsing remitting MS (RRMS); Secondary progressive MS (SPMS); T1 weighted hypointense lesions; T2 weighted hyperintense lesions

Indexed keywords

GADOLINIUM; THALLIUM;

BRAIN ATROPHY; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; CONTRAST ENHANCEMENT; CORRELATION ANALYSIS; DEMYELINATION; DIAGNOSTIC IMAGING; DIFFUSION WEIGHTED IMAGING; DISABILITY; DISEASE MARKER; HUMAN; INFLAMMATION; MULTIPLE SCLEROSIS; NERVE CELL LESION; NERVE FIBER; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY;

AXONS; BRAIN; CLINICAL TRIALS; HUMANS; MAGNETIC RESONANCE IMAGING;

EID: 5444272770     PISSN: 09391517     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-004-1403-2     Document Type: Conference Paper

References (46)

1. Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, Antel JP (1994) Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 36:76-82
2. Bakshi R, Benedict RH, Bermel RA, Jacobs L (2001) Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings. J Neuroimaging 11:129-136
3. Bakshi R, Czarnecki D, Shaikh ZA, Priore RL, Janardhan V, Kaliszky Z, Kinkel PR (2000) Brain MRI lesions and atrophy are related to depression in multiple sclerosis. Neuroreport 11:1153-1158
4. Barkhof F (2002) The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 15:239-245
5. Barkhof F, van Waesberghe JH, Filippi M, Yousry T, Miller DH, Hahn D, Thompson AJ, Kappos L, Brex P, Pozzilli C, Polman CH (2001) T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 124:1396-1402
6. Bermel RA, Bakshi R, Tjoa C, Puli SR, Jacobs L (2002) Bicaudate ratio as a magnetic resonance imaging marker of brain atrophy in multiple sclerosis. Arch Neurol 59:275-280
7. Bjartmar C, Kidd G, Mork S, Rudick R, Trapp BD (2000) Neurological disability correlates with spinal cord axonal loss and reduced N-acetyl aspartate in chronic multiple sclerosis patients. Ann Neurol 48:893-901
8. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158-164
9. Chard DT, Griffin CM, McLean MA, Kapeller P, Kapoor R, Thompson AJ, Miller DH (2002) Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain 125:2342-2352
10. Christodoulou C, Krupp LB, Liang Z, Huang W, Melville P, Roque C, Scherl WF, Morgan T, MacAllister WS, Li L, Tudorica LA, Li X, Roche P, Peyster R (2003) Cognitive performance and MR markers of cerebral injury in cognitively impaired MS patients. Neurology 60:1793-1798
11. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, Miller D, Waldmann H, Compston A (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46:296-304
12. Comi G, Inglese M, De Stefano N, Smith S, Barkhof F, Durelli L, et al. (2002) Brain volume changes in patients at presentation with suspected multiple sclerosis: results from the ETOMS study. Lancet (in press)
13. Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290-297
14. Dautry C, Vaufrey F, Brouillet E, Bizat N, Henry PG, Conde F, Bloch G, Hantraye P (2000) Early N-acetylaspartate depletion is a marker of neuronal dysfunction in rats and primates chronically treated with the mitochondrial toxin 3-nitropropionic acid. J Cereb Blood Flow Metab 20:789-799
15. De Stefano N, Matthews PM, Filippi M, Agosta F, De Luca M, Bartolozzi ML, Guidi L, Ghezzi A, Montanari E, Cifelli A, Federico A, Smith SM (2003) Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 60:1157-1162
16. Filippi M, Iannucci G, Tortorella C, Minicucci L, Horsfield MA, Colombo B, Sormani MP, Comi G (1999) Comparison of MS clinical phenotypes using conventional and magnetization transfer MRI. Neurology 52:588-594
17. Filippi M, Rocca MA (2003) Disturbed function and plasticity in multiple sclerosis as gleaned from functional magnetic resonance imaging. Curr Opin Neurol 16:275-282
18. Filippi M, Rovaris M, Rocca MA, Sormani MP, Wolinsky JS, Comi G (2001) Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 57:731-733
19. Fisher E, Rudick RA, Cutter G, Baier M, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA (2000) Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients. Mult Scler 6:373-377
20. Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA (2002) Eight-year follow-up study of brain atrophy in patients with MS. Neurology 59:1412-1420
21. Fu L, Wolfson C, Worsley KJ, De Stefano N, Collins DL, Narayanan S, Arnold DL (1996) Statistics for investigation of multimodal MR imaging data and an application to multiple sclerosis patients. NMR Biomed 9:339-346
22. Giugni E, Pozzilli C, Bastianello S, Gasperini C, Paolillo A, Koudriavtseva T, Frontoni M, Farina D, Bozzao L (1997) MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler 3:221-225
23. Grimaud J, Barker GJ, Wang L, Lai M, MacManus DG, Webb SL, Thompson AJ, McDonald WI, Tofts PS, Miller DH (1999) Correlation of magnetic resonance imaging parameters with clinical disability in multiple sclerosis: a preliminary study. J Neurol 246:961-967
24. Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H (2000) The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. J Neuroimmunol 107:161-166
25. Janardhan V, Bakshi R (2000) Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. Arch Neurol 57:1485-1491
26. Jones CK, Riddehough A, Li DKB, Zhao GJ, Paty DW (2001) MRI cerebral atrophy in relapsing-remitting MS: Results from the PRISMS trial. Neurol 56:A379 (Abstract)
27. Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R (2003) Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 53:292-304
28. Koudriavtseva T, Thompson AJ, Fiorelli M, Gasperini C, Bastianello S, Bozzao A, Paolillo A, Pisani A, Galgani S, Pozzilli C (1997) Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 62:285-287
29. Lin X, Tench CR, Turner B, Blumhardt LD, Constantinescu CS (2003) Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry 74:1090-1094
30. McFarland HF (2002) The emerging role of MRI in multiple sclerosis and the new diagnostic criteria. Mult Scler 8:71-72
31. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ (2002) Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 125:1676-1695
32. Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH (2000) The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 123:2256-2263
33. Narayanan S, De Stefano N, Francis GS, Arnaoutelis R, Caramanos Z, Collins DL, Pelletier D, Arnason BGW, Antel JP, Arnold DL (2001) Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b. J Neurol 248:979-986
34. O'Riordan JI, Gawne CM, Coles A, Wang L, Compston DA, Tofts P, Miller DH (1998) T1 hypointense lesion load in secondary progressive multiple sclerosis: a comparison of pre versus post contrast loads and of manual versus semi automated threshold techniques for lesion segmentation. Mult Scler 4:408-412
35. Paolillo A, Bastianello S, Frontoni M, Gasperini C, Giugni E, Ciccarelli O, Luccichenti G, Cannoni S, Pozzilli C (1999) Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. J Neurol 246:443-448
36. Parry A, Corkill R, Blamire AM, Palace J, Narayanan S, Arnold D, Styles P, Matthews PM (2003) Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis. J Neurol 250:171-178
37. Peterson JW, Bo L, Mork S, Chang A, Trapp BD (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50:389-400
38. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M (2001) Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 124:1803-1812
39. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53:1698-1704
40. Sailer M, Fischl B, Salat D, Tempelmann C, Schonfeld MA, Busa E, Bodammer N, Heinze HJ, Dale A (2003) Focal thinning of the cerebral cortex in multiple sclerosis. Brain 126:1734-1744
41. Sarchielli P, Presciutti O, Tarducci R, Gobbi G, Alberti A, Pelliccioli GP, Orlacchio A, Gallai V (1998) 1H-MRS in patients with multiple sclerosis undergoing treatment with interferon beta1a: results of a preliminary study. J Neurol Neurosurg Psychiatry 64:204-212
42. Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Sheeder J, Miller D, McCabe K, Serra A, Campion MK, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE III. (2000) A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 55:185-192
43. Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, Polman CH, Hommes OR, Ader HJ, Barkhof F (1996) Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology 47:1469-1476
44. Turner B, Lin X, Calmon G, Roberts N, Blumhardt LD (2003) Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler 9:21-27
45. van Walderveen MA, Barkhof F, Pouwels PJ, van Schijndel RA, Polman CH, Castelijns JA (1999) Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. Ann Neurol 46:79-87
46. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M (2001) Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 57:1239-1247